Bridgewater Advisors Inc. Makes New Investment in Sanofi (NASDAQ:SNY)

Bridgewater Advisors Inc. purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,273 shares of the company's stock, valued at approximately $391,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cardinal Capital Management lifted its holdings in Sanofi by 0.3% during the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock worth $3,827,000 after purchasing an additional 199 shares in the last quarter. Gradient Investments LLC increased its position in shares of Sanofi by 2.1% during the 1st quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after purchasing an additional 200 shares during the last quarter. Providence Capital Advisors LLC grew its position in Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after acquiring an additional 201 shares during the last quarter. Perigon Wealth Management LLC grew its position in Sanofi by 3.1% during the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock worth $367,000 after acquiring an additional 201 shares during the last quarter. Finally, Beacon Financial Group grew its position in Sanofi by 1.6% during the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock worth $799,000 after acquiring an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of "Buy" and an average price target of $61.50.

Sanofi Stock Performance

Shares of SNY traded up $0.13 during trading hours on Thursday, hitting $48.65. The stock had a trading volume of 1,738,702 shares, compared to its average volume of 2,324,868. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The firm has a market capitalization of $119.31 billion, a PE ratio of 17.38, a PEG ratio of 1.11 and a beta of 0.48. The stock has a fifty day moving average price of $49.76 and a 200 day moving average price of $52.08.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the business earned $1.78 earnings per share. The business's revenue was down 11.0% on a year-over-year basis. Analysts anticipate that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.